Markets

Immutep Presents ePoster At European Society For Medical Oncology Congress 2026 For Its Eftilagimod Alfa In Combination With KEYTRUDA

Oct 23, 2026 · 08:02 AM ET· updated 55m ago

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced health-related quality of life

Why It Matters

Immutep shared research results about its cancer medicine at a big doctor conference. When a company shows new data publicly, watch for whether doctors think it works well.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

IMMP3.17

-0.11 (-3.35%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.